BTIG reiterates Buy on Maze Therapeutics, $46 price target
BTIG reiterated a Buy rating on Maze Therapeutics and set a $46.00 price target, implying 105.4% upside versus the Sep 21 close of $22.39.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.